GLP-1 Receptor Agonists Drugs

Trulicity (dulaglutide) is a medication in a class called GLP-1 receptor agonists. It is used alongside diet and exercise to help adults and children aged 10 and older with type 2 diabetes manage their blood sugar levels. Additionally, for adults with type 2 diabetes who have heart disease or risk factors, Trulicity can help lower their risk of serious heart problems like heart attack or stroke.

Exenatide (brand name: Exenatide) is a medication in the GLP-1 receptor agonist class, used to help adults with type 2 diabetes manage their blood sugar levels. It works by mimicking a natural hormone in your body that helps release insulin when your blood sugar is high, thereby improving glycemic control when used with diet and exercise.

Liraglutide (Victoza) is a type of medicine that mimics a natural hormone in your body. It is prescribed to help adults and children aged 10 and older with type 2 diabetes manage their blood sugar levels, and it can also lower the risk of serious heart problems like heart attack or stroke in adults with type 2 diabetes and existing heart disease. It works by helping your body release insulin when needed and reducing the amount of sugar your liver makes.

Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist approved for type 2 diabetes, weight management, and cardiovascular risk reduction. See the full semaglutide monograph for complete prescribing information.

Semaglutide is a once-weekly (or once-daily oral) GLP-1 receptor agonist that lowers blood sugar and reduces body weight by mimicking the natural gut hormone GLP-1. It is sold under three brand names — Ozempic (injectable, type 2 diabetes), Wegovy (injectable, weight management), and Rybelsus (oral tablet, type 2 diabetes) — all manufactured by Novo Nordisk. Clinical trials show it reduces HbA1c by up to 2.0 percentage points and body weight by up to 15% at the highest injectable dose.

Tirzepatide is a once-weekly injectable prescription medication that activates both the GIP and GLP-1 hormone receptors — making it the first dual GIP/GLP-1 receptor agonist approved by the FDA. It is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea. Clinical trials show it reduces HbA1c by up to 2.58 percentage points and body weight by up to 20.9% at the highest dose.